Definition

A preparation of autologous human T lymphocytes genetically modified to express a chimeric endocrine receptor (CER) targeting the human follicle stimulating hormone receptor (FSHR) and coupled to the signaling domains of 4-1BB (CD137) and CD3 zeta, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous anti-FSHR CER-4-1BB/CD3zeta-expressing T lymphocytes target and bind to the FSHR on FSHR-expressing tumor cell surfaces, thereby killing FSHR-expressing tumor cells. FSHR is not normally expressed in healthy non-ovarian tissue, but is present on several types of ovarian, fallopian tube, or primary peritoneal cancers.